PE20211774A1 - Piridazinonas y sus metodos de uso - Google Patents

Piridazinonas y sus metodos de uso

Info

Publication number
PE20211774A1
PE20211774A1 PE2021000320A PE2021000320A PE20211774A1 PE 20211774 A1 PE20211774 A1 PE 20211774A1 PE 2021000320 A PE2021000320 A PE 2021000320A PE 2021000320 A PE2021000320 A PE 2021000320A PE 20211774 A1 PE20211774 A1 PE 20211774A1
Authority
PE
Peru
Prior art keywords
hydrogen
pyridazinones
methods
fluorophenyl
double bond
Prior art date
Application number
PE2021000320A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Jean-Christophe P Harmange
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of PE20211774A1 publication Critical patent/PE20211774A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de formula (I) donde "--- " es un enlace simple o enlace doble, X1 puede ser CH, N; X 2 puede ser CH o N, N (CH3) entre otros; Y puede ser -0-, ciclopropano-1, 1-diilo entre otros, Q es 2-trifluorometil-4-fluorofenilo, 2-difluorometil-4-fluorofenilo; R 3 es hidrogeno; y cuando "--- " es un enlace doble, R 4 esta ausente; y cuando "--- " es un enlace sencillo, R 3 y R 4 se toman juntos para formar = 0; y cada uno de R 5 y R 6 es independientemente hidrogeno o -CH 3 ,siempre que si X 1 es N, X 2 es N, Y es -O- o -N (CH 3 ) - y Q es 2-trifluorometilfenilo, entonces al menos uno de R 3 , R 5 y R 6 no es hidrogeno. Composiciones farmaceuticas relacionadas. Tambien se utilizan para tratar enfermedades renales.
PE2021000320A 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso PE20211774A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17
PCT/US2019/051680 WO2020061162A1 (en) 2018-09-18 2019-09-18 Pyridazinones and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20211774A1 true PE20211774A1 (es) 2021-09-08

Family

ID=69887813

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000320A PE20211774A1 (es) 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso

Country Status (23)

Country Link
US (3) US10654850B2 (es)
EP (1) EP3852533B1 (es)
JP (1) JP7474243B2 (es)
KR (1) KR20210069652A (es)
CN (1) CN112911935A (es)
AU (1) AU2019344928A1 (es)
BR (1) BR112021004926A2 (es)
CA (1) CA3113236A1 (es)
CL (1) CL2021000648A1 (es)
CO (1) CO2021004789A2 (es)
DK (1) DK3852533T3 (es)
EC (1) ECSP21026485A (es)
FI (1) FI3852533T3 (es)
IL (1) IL281438B2 (es)
LT (1) LT3852533T (es)
MX (1) MX2021003152A (es)
PE (1) PE20211774A1 (es)
PH (1) PH12021550443A1 (es)
PT (1) PT3852533T (es)
SG (1) SG11202102053VA (es)
TW (1) TWI828758B (es)
UY (1) UY38377A (es)
WO (1) WO2020061162A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654850B2 (en) 2018-09-18 2020-05-19 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
EP4174069A1 (en) * 2020-07-03 2023-05-03 Wuhan LL Science and Technology Development Co., Ltd. Heterocyclic compound and use thereof
CN114907408B (zh) * 2021-02-07 2024-05-03 武汉朗来科技发展有限公司 一种杂环化合物、其中间体、其制备方法及其应用
CN117940417A (zh) * 2021-09-10 2024-04-26 南京明德新药研发有限公司 卤素取代的哒嗪酮类化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7491713B2 (en) 2004-01-29 2009-02-17 Merck + Co., Inc. CGRP receptor antagonists
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
CA2583536A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
ES2397283T3 (es) 2006-07-25 2013-03-06 Cephalon, Inc. Derivados de piridizinona
WO2008115385A2 (en) 2007-03-15 2008-09-25 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
MX2010004705A (es) * 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
KR20180031823A (ko) * 2010-09-01 2018-03-28 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
CA2874953A1 (en) * 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6667093B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピリド[2,3−d]ピリミジン−2,4(1H,3H)−ジオン誘導体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CA3075727A1 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
US10654850B2 (en) 2018-09-18 2020-05-19 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
AU2020240059A1 (en) * 2019-03-20 2021-10-28 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms

Also Published As

Publication number Publication date
KR20210069652A (ko) 2021-06-11
CN112911935A (zh) 2021-06-04
PT3852533T (pt) 2024-05-31
DK3852533T3 (da) 2024-05-27
JP7474243B2 (ja) 2024-04-24
EP3852533A1 (en) 2021-07-28
WO2020061162A1 (en) 2020-03-26
EP3852533B1 (en) 2024-02-28
CO2021004789A2 (es) 2021-07-30
FI3852533T3 (fi) 2024-05-24
LT3852533T (lt) 2024-06-10
IL281438B1 (en) 2023-08-01
CA3113236A1 (en) 2020-03-26
UY38377A (es) 2020-04-30
US20220024917A1 (en) 2022-01-27
CL2021000648A1 (es) 2021-08-06
TW202035402A (zh) 2020-10-01
BR112021004926A2 (pt) 2021-06-01
US10654850B2 (en) 2020-05-19
JP2022500359A (ja) 2022-01-04
AU2019344928A1 (en) 2021-04-29
US11046690B2 (en) 2021-06-29
IL281438A (en) 2021-04-29
MX2021003152A (es) 2021-06-23
SG11202102053VA (en) 2021-04-29
TWI828758B (zh) 2024-01-11
US20200283437A1 (en) 2020-09-10
EP3852533A4 (en) 2022-06-15
IL281438B2 (en) 2023-12-01
ECSP21026485A (es) 2021-07-30
US20200102301A1 (en) 2020-04-02
PH12021550443A1 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
PE20211774A1 (es) Piridazinonas y sus metodos de uso
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
UY38979A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
UY38525A (es) 1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas
AR090670A1 (es) Compuestos herbicidas
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
EA202192405A1 (ru) Составы антител против il-36r
PE20221901A1 (es) Un compuesto aromatico sustituido con anillo fundido, metodo de preparacion, composicion herbicida y su uso
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
BR112021020027A2 (pt) Compostos, composições e métodos
CO2022004341A2 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
PA8782901A1 (es) "nuevos compuestos ligandos del receptor de la adenosina a3"
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
CL2019002661A1 (es) Compuestos antineoplásicos.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
ECSP099679A (es) Nuevos compuestos y sus usos 707
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.